{"contentid": 488737, "importid": NaN, "name": "Keytruda, Lynparza and Lenvima central to Merck & Co\u00e2\u0080\u0099s ASCO offering", "introduction": "US pharma major Merck & Co\u00e2\u0080\u0099s presentations at this year\u00e2\u0080\u0099s ASCO annual meeting will focus primarily on three products.", "content": "<p>US pharma major Merck &amp; Co&rsquo;s (NYSE: MRK) presentations at this year&rsquo;s ASCO annual meeting will focus primarily on three products.</p>\n<p>These drugs are the anti-PD-1 blockbuster Keytruda (pembrolizumab), the PARP inhibitor partnered with AstraZeneca (LSE: AZN), Lynparza (olaparib) and Lenvima (lenvatinib), a multiple kinase inhibitor that was originally developed by Eisai (TYO: 4523).</p>\n<p><span class=\"pullQuote\">\"At this year&rsquo;s ASCO, we will present new clinical and real-world data highlighting how our oncology medicines are making a meaningful impact on the lives of people with cancer and driving forward future innovations in cancer care\"</span>New Phase III data will be presented from the KEYNOTE-564 trial evaluating Keytruda as an adjuvant treatment for renal cell carcinoma (RCC) following nephrectomy and from the KEYNOTE-811 study of the same drug alongside trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for locally advanced unresectable or metastatic high-risk human epidermal growth factor receptor 2-positive gastric or gastroesophageal junction adenocarcinoma.</p>\n<p>Merck will also present first-time data from the Phase III OlympiA trial evaluating Lynparza as an adjuvant treatment for patients with germline BRCA-mutated high-risk HER2-negative early-stage breast cancer following definitive local treatment and neoadjuvant or adjuvant chemotherapy.</p>\n<p>There will be further data on the combination of Keytruda and Lenvima as a second-line treatment for patients with melanoma who progressed on anti-PD-1/PD-L1 therapy, for certain patients with advanced endometrial cancer following at least one prior platinum-based chemotherapy regimen in any setting, and as a first-line option for advanced RCC.</p>\n<p>From Merck&rsquo;s pipeline, the company will present updated findings from a Phase II study evaluating belzutifan for treatment of von Hippel-Lindau disease-associated clear cell RCC.</p>\n<p>Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said: \"Our expansive oncology clinical development program is designed to help us understand the full potential of our established and pipeline medicines and identify new avenues of treatment, including in earlier lines of therapy and in combination with other oncology therapies.</p>\n<p>\"At this year&rsquo;s ASCO, we will present new clinical and real-world data highlighting how our oncology medicines are making a meaningful impact on the lives of people with cancer and driving forward future innovations in cancer care.\"</p>", "date": "2021-05-25 16:50:00", "meta_title": NaN, "meta_keywords": "ASCO, Merck, cancer, treatment, Keytruda, data, Lynparza, Lenvima, Co\u00e2\u0080\u0099s, present, clinical, oncology, years, central, offering, primarily, meeting, focus", "meta_description": "US pharma major Merck & Co\u00e2\u0080\u0099s presentations at this year\u00e2\u0080\u0099s ASCO annual meeting will focus primarily on three products.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-25 16:38:14", "updated": "2021-05-25 17:14:24", "access": NaN, "url": "https://www.thepharmaletter.com/article/keytruda-lynparza-and-lenvima-central-to-merck-co-s-asco-offering", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "merck_large.jpg", "image2id": "merck_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology, Oncology", "topic_tag": "ASCO, Conferences, Drug Trial, Research", "geography_tag": "USA", "company_tag": "Merck & Co", "drug_tag": "Keytruda, Lenvima, Lynparza", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-25 16:50:00"}